A:

In 1982,

The U.S. Food and Drug Administration (FDA) recognized the lack of incentive for pharmaceutical companies to develop cures for rare diseases and established the Office of Orphan Product Development. This branch of the FDA provides incentives to companies that work toward curing rare diseases by exercising the rights given to them under the Orphan Drug Act of January 1983. One type of incentive is the orphan drug status, which provides tax reductions and the exclusive right to develop the cure for a specific condition for a period of seven years to companies attempting to cure rare diseases.

Developing drugs to treat the vast number of diseases in the world is a line of business that can lead to massive fortunes, but unfortunately not all developed drugs become the golden ticket. In the world pharmaceuticals, the largest amount of money can be made by developing drugs that become the standard for curing common diseases.

From a business perspective, having a large market ensures that a company can quickly recuperate the cost of development and can also realize the largest possible gain. For this reason, there is little incentive for pharmaceutical companies to develop cures for rare diseases - those that affect fewer than 200,000 people in the United States - because the small market and high cost associated with finding these types of cures discourages these companies from entering this market.

For related reading, check out Measuring The Medicine Makers.

RELATED FAQS
  1. How does government regulation impact the drugs sector?

    Learn about how drugs are regulated by the U.S. government as well as the role of the Food and Drug Administration during ... Read Answer >>
  2. What is the drugs sector?

    Learn more about the drug industry and how new drugs are brought to market. Find out about how drug research is financed ... Read Answer >>
  3. What process does a company need to follow to bring a new drug to market?

    Learn about the costly price of bringing new drugs to market. Discover why the pharmaceutical industry invests billions of ... Read Answer >>
  4. What countries comprise the majority of the global drugs sector?

    Find out which countries are the largest producers of pharmaceutical products in the world and why the United States dominates ... Read Answer >>
  5. How does the drug sector benefit from the growth of emerging markets?

    Understand how the pharmaceutical industry benefits from the growth of emerging markets. Benefits are linked to growing economies ... Read Answer >>
  6. What are the primary factors that drive share prices in the drugs sector?

    Learn about the primary factors that drive share prices in the drug sector. Creating and manufacturing drugs is a complex ... Read Answer >>
Related Articles
  1. Investing

    Orphan Drug Rules Are Being Manipulated

    It may be the time to revamp the Orphan Drug Program amid concerns it's turning into a scam.
  2. Investing

    Senator Orders Investigation of Orphan Drug Abuse

    Iowa Senator Grassley ordered an inquiry into possible abuse of the Orphan Drug Act by drug makers.
  3. Investing

    3 of America's Most Expensive Drugs and Who Profits From Them

    Learn about orphan drugs that are some of the most expensive drugs in America. Read about the companies that manufacture these drugs.
  4. Investing

    Evaluating Pharmaceutical Companies

    Learn how to find a healthy pharmaceutical investment in a market full of weak drugs.
  5. Investing

    A Primer On The Biotech Sector

    Investing in the biotech sector can involve both huge losses and major gains.
  6. Investing

    aTyr Pharma Rises 16% on Orphan Drug Status

    Atyr Pharma was granted orphan drug status for its Resolaris muscular dystrophy drug.
  7. Insights

    Sarepta’s Exondys 51 Drug May Cost $300,000 (SRPT)

    Following FDA approval, industry speculation is running high about the possible price of Sarepta's muscular dystrophy Exondys 51 drug.
  8. Investing

    Cytori Scleroderma Wins Orphan Drug Status (CYTX)

    Cytori Therapeutics secured orphan drug status for its ECCS-50 drug to treat scleroderma.
  9. Investing

    Investing In The Biotech Sector

    The biotech sector is more than just medical research. Read this before you invest.
RELATED TERMS
  1. Orphan Drug Credit

    A federal tax credit that provides an incentive for pharmaceutical ...
  2. Orphan Drug

    A drug or biological product that treats a rare condition or ...
  3. Food And Drug Administration - FDA

    A government agency established in 1906 with the passage of the ...
  4. New Drug Application (NDA)

    The final step formally taken by a drug sponsor, wherein it applies ...
  5. New Indications

    A term used by medical companies and professionals to signify ...
  6. Disease Management Program

    Disease management programs can help control health care expenses ...
Hot Definitions
  1. Trumpcare

    The American Health Care Act, also known as Trumpcare and Ryancare, is the Republican proposal to replace Obamacare.
  2. Free Carrier - FCA

    A trade term requiring the seller to deliver goods to a named airport, terminal, or other place where the carrier operates. ...
  3. Portable Alpha

    A strategy in which portfolio managers separate alpha from beta by investing in securities that differ from the market index ...
  4. Run Rate

    1. How the financial performance of a company would look if you were to extrapolate current results out over a certain period ...
  5. Hard Fork

    A hard fork (or sometimes hardfork) is a radical change to the protocol that makes previously invalid blocks/transactions ...
  6. Interest Rate Risk

    The risk that an investment's value will change due to a change in the absolute level of interest rates, in the spread between ...
Trading Center